Market
Forecast:
The expanding
biotechnology and biopharmaceutical sector are driving the growth of this
market. For instance, firms in the U.S. firms perform extensive R&D in
pharmaceuticals which is approximately USD 75 billion.
Registering
a CAGR of 8.6%, the global Cell
Lysis & Disruption Market is expected to reach USD 5.7 billion in
by 2025.
The rising demand for cellular disruption is increasing the growth
of the biotechnology and biopharmaceutical sector globally. Moreover, advancements
in the field of proteomics, metabolomics, and personalized medicine are rising
the adoption of cell lysis techniques. Furthermore, governments in countries
such as China, India, South Africa, and Russia are investing heavily in the biotech
industry, providing a destination for clinical trials, contract research, and
manufacturing activities.
·
Bio-Rad
Laboratories
·
Miltenyi Biotec
Segmentation:
·
The global cell lysis & disruption market
has been segmented into technique, product, cell type, and end user.
·
By technique, the market has been segmented
segregated into reagent based and physical disruption. The reagent based
segment is further segmented into detergent
and enzymatic.
·
By product, the market has been bifurcated
into consumables and instruments. The consumables segment is estimated to hold
major market share in the market due to the rise in funding of cell based
research. Consumables has been further divided into reagent and kits, beads and
disposables. The instrument segment has been further categorized as sonicators,
homogenizers, French press, microfluidizer,
and others.
·
On the basis of cell type, the global cell
lysis & disruption market has been classified as mammalian cells, microbial
cells, and others.
·
The global cell lysis & disruption
market, by end user, has been divided into research laboratories and
institutes, pharmaceutical and biotechnology companies,
and others.
Regional
Analysis:
On
regional basis, the Americas is anticipated to dominate the global cell lysis
& disruption market owing to the growing clinical R&D budgets by both
government as well as public and private organizations in pharmaceutical and
biotech sector and increasing demand for novel therapeutics in the region. Additionally, the rising prevalence of
geriatric population along with various chronic diseases is contributing the
growth of this market. According to a report by the Population Reference
Bureau, the number of older population (aged 65 and above) will rise to nearly
24% from 15% by 2060.Europe is expected to hold the second-
largest position in the global cell lysis & disruption market
owing to the presence of a strong academic & research base and availability
of funding for research in the European countries. Moreover, rising healthcare
expenditure is boosting the market in this region.
No comments:
Post a Comment